the aid library

LIST OPTIONS

Filter

8840

Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern

European Centre for Disease Prevention and Control ECDC (2022) CC

Wearing a face mask can help reduce the spread of COVID-19 in the community by reducing the release of respiratory droplets from asymptomatic / pre-symptomatic individuals or those with mild non-specific symptoms. The use of face masks for this purpose may be adopted to reduce the societal impact as... more

Download (189)

View PDF (179)

Operational considerations for the provision of the HIV continuum of care

European Centre for Disease Prevention and Control ECDC (2022) C1

This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA. This document has two aims: firstly, to outline what is known of the Ukrainian HIV epidemic, and secondly, to use the HIV continuum o... more

External Link

Chagas Clinical Research Platform Newsletter

Drugs for Neglected Diseases Initiative DNDi Latin America (2022) CC

To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Cha... more

Download (144)

View PDF (187)

Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial

Pohlig G, Bernhard SC, Blum J, Burri C, Mpanya A, et al. PLOS Neclected Tropical Diseases (2016) CC

This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita... more

External Link

Full prescribing information Fexinidazole tablets, for oral use

Drugs for Neglected Diseases initiative DNDi (2021) C1

Full Perscribing information on Fexinidazole Tablet for oral use INDICATIONS AND USAGE Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati... more

External Link

DNDi Strategic Plan 2021-2028 | DNDi - English version

DNDi - Drugs for neglected diseases initiative (2023) C2

Accessed on 04.04.2023 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients

External Link

Certified African Regional professionals: Level 1 Biological Waste Management

Africa Center for Disease Control and Prevention (2023) CC

The Africa Centres for Disease Control and Prevention (Africa CDC) Biosafety and Biosecurity Initiative was launched by the Africa CDC in April 2019 with the aim of strengthening the African Union (AU) Member States’ biosafety and biosecurity syst... more

Secondhand Smoke Exposure and the Impact of Smokefree Policies

Centers for Disease Control and Prevention (2021) CC

The Public Health Burden of Secondhand Exposure to Commercial Tobacco Smoke Secondhand smoke, the combination of smoke from burning commercial tobacco* products and the smoke breathed out by a person who is smoking, is deadly.

African Union AMR Landmark Report: Voicing African Priorities on the Active Pandemic

Africa Center for Disease Control and Prevention (2024) CC

Antimicrobial resistance (AMR) has emerged as a leading cause of death in the African region, surpassing fatalities from malaria, HIV, and TB. In response to this critical threat, the region has adopted the AMR Global Action Plan and the African Union Framework for Antimicrobial Resistance Control 2...020 – 2025, which is tailored to meet the specific needs of African nations through a coordinated approach. While most countries in the region have developed and prioritized National Action Plans (NAPs) to tackle AMR, the overall response remains inadequate given the magnitude of the threat, which endangers human, animal, environmental, aquatic, and plant health. Africa bears a significant burden of infectious diseases, accounting for approximately 95% of malaria deaths, 70% of people living with HIV, and 25% of TB deaths globally. In 2019, AMR was linked to approximately 55,000 deaths from HIV, 30,000 from malaria, and 255,000 overall. Major drivers of AMR in the region include the overuse and misuse of antimicrobials in human and food systems, migration, suboptimal vaccination rates, and environmental contamination from hospital and pharmaceutical effluents. Additionally, there is a lack of access to quality-assured antimicrobials and diagnostics, compounded by inadequate knowledge about AMR. Unlike high-income countries, where indiscriminate antimicrobial use is the primary factor driving AMR, African countries face additional challenges, including a lack of access to clean and safe water, poor Water, Sanitation, and Hygiene (WASH) programs, inadequate infection prevention measures, and suboptimal vaccinations for preventable diseases. One in three hospitals in the region lacks clean, safe running water, and one in eight people defecate openly due to inadequate sanitation. Investments in WASH, infection prevention, and biosecurity could save approximately 700,000 lives annually. Addressing AMR in Africa requires a comprehensive, multi-sectoral approach involving the entire society. Sustainable access to antimicrobials, including antibiotics, vaccines, and therapeutics, is crucial, as lack of access leads to more morbidity and mortality than AMR itself. Support for the region should focus on preventing infections, strengthening health and food systems, developing human resources, ensuring sustainable access to diagnostics and therapeutics, and investing in laboratory infrastructure to support surveillance and data generation. more

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like ... occurred in monkeys kept for research. The first human case was recorded in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Download (159)

View PDF (162)

Strategies for Identifying and Linking HIV-Infected Infants, Children, and Adolescents to HIV Care and Treatment

Centers for Diseases Control and Prevention; USAID (2019) C_CDC

Accessed: 08.10.2019

Download (426)

View PDF (900)

Nigeria: Preparedness and Response to Acute Watery Diarrhoea Outbreaks

Federal Ministry of Health - Nigeria Centre for Disease Control (2017) C2

A GUIDE FOR HEALTH WORKERS AND AUTHORITIES IN NIGERIA

Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis

José A. Caminero International Union Against Tuberculosis and Lung Disease (The Union) (2013)

Download (441)

View PDF (738)

Nigeria: Preparedness and Response to Cerebrospinal Meningitis Outbreaks

Federal Ministry Of Health - Nigeria Centre for Disease Control (2017) C2

A GUIDE FOR HEALTH WORKERS AND AUTHORITIES IN NIGERIA

Download (292)

View PDF (719)

Best Practice for the Care of Patients with Tuberculosis: a Guide for Low-Income Countries
recommended

G. Williams, E. Alarcón, S. Jittimanee et al. The International Union Against Tuberculosis and Lung Disease (2017) CC

2nd edition. The practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide

Download (124)

View PDF (152)

Optimization of ART in Ukraine: general principles of ART optimization from a public health perspective

Professor J. Lundgren World Health Organization (Europe); Centre for Health & Infectious Disease Research (2016) C_WHO

Mission report April 2016

Download (99)

View PDF (136)

Acentres africains de contrôle et de prévention des - Response a la pandemie COVID- 19 pour les etatas mebres - Recommandations selon les differentes phases

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C2

Accessed: 31.03.2020

Reponse à la pandémie COVID- 19 pour les états membres.

African Union; Africa CDC Centres for Disease Control and Prevention; World Health Organization WHO, et al. (2020) C1

Mars 2020. Recommendations selon les differentes phases

Priorities for Tuberculosis Bacteriology Services in Low-Income Countries International Union

Hans L. Rieder, Armand Van Deun, Kai Man Kam, Sang Jae Kim, T. Martin Chonde, Arnaud Trébucq, Richard Urbanczik International Union Against Tuberculosis and Lung Disease (2007) CC

Second Edition

Download (4309)

View PDF (2304)

Philippines: Leptospirosis Guidelines
recommended

Manolito L. Chua, Marissa M. Alejandria Philippine Society for Microbiology and Infectious Diseases (2010) C1

Best Practice for the Care of Patients with Tuberculosis: a Guide for Low-Income Countries recommended

Philippines: Leptospirosis Guidelines recommended

Best Practice for the Care of Patients with Tuberculosis: a Guide for Low-Income Countries
recommended

Philippines: Leptospirosis Guidelines
recommended